POM-V Prescription Required

Zeleris 400 mg/ml + 5 mg/ml Solution for Injection for Cattle

Active ingredients: Florfenicol, Meloxicam

Form

Injection

Species

Cattle

Manufacturer

Ceva Animal Health Ltd

VMD MA No.

15052/5026

What it's used for

For therapeutic treatment of bovine respiratory disease (BRD) due Histophilus somni, Mannheimia haemolytica, Pasteurella multocida and Mycoplasma bovisasso...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Florfenicol + Meloxicam

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Zeleris 400 mg/ml + 5 mg/ml Solution for Injection for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

For therapeutic treatment of bovine respiratory disease (BRD) due Histophilus somni,
Mannheimia haemolytica, Pasteurella multocida and Mycoplasma bovisassociated with
pyrexia.

Do not use in adult bulls intended for breeding.
Do not use in animals suffering from impaired hepatic, cardiac or renal function and
haemorrhagic disorders, or when there is evidence of ulcerogenic gastrointestinal
lesions.
Do not use in case of hypersensitivity to the active substances or to any of the excipients.

Cattle:
Very common
(>1 animal / 10 animals treated):
Injection site swelling, Injection site induration,
Injection site warmth, Injection site pain*
Undetermined frequency
(cannot be estimated from the
available data):
Immediate pain upon injection**
* Usually resolve without treatment within 5 to 15 days but could persist up to 49 days.
** Pain at injection site is of moderate severity and manifested as head or neck
movement.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See also the last section ‘Contact details’ of the package
leaflet

Revised: August 2023
AN: 00510/2022

There is no bacterial eradication of Mycoplasma bovis. Clinical efficacy against M. bovis
has only been demonstrated in mixed infections.

Revised: August 2023
AN: 00510/2022

i) Special precautions for use in animals
Use of the product should be based on identification and susceptibility testing of the
target pathogen(s). If this is not possible, therapy should be based on epidemiological
information and knowledge of susceptibility of the target pathogens at farm level, or at
local/regional level.
Use of the product should be in accordance with official, national and regional
antimicrobial policies.
An antibiotic with a lower risk of antimicrobial resistance selection (lower AMEG category)
should be used for first line treatment where susceptibility testing suggests the likely
efficacy of this approach.
Not for use for prophylaxis or metaphylaxis.
Avoid use in severely dehydrated, hypovolaemic or hypotensive animals, as there may
be a potential risk of renal toxicity. In the absence of safety data it is not recommended to
use the product in calves less than 4 weeks old.
ii) Special precautions to be taken by the person administering the veterinary
medicinal product to animals
The product is slightly irritant to the eye. Rinse any splashes from eyes immediately with
plenty of water.
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
People with known hypersensitivity to florfenicol, meloxicam or to any of the excipients
should avoid contact with the veterinary medicinal product.
Dose dependent maternotoxic and foetotoxic effects have been observed after oral
administration of meloxicam to pregnant rats. Therefore, the veterinary medicinal product
should not be administered by pregnant women.
Special precautions for the protection of the environment:
Not applicable.

Do not administer concurrently with glucocorticoids, other non-steroidal anti-inflammatory
drugs or with anticoagulant agents.

This veterinary medicinal product does not require any special storage conditions.

Meat and offal: 56 days.
Milk: Not authorised for use in animals producing milk for human consumption. Do not
use in pregnant cows, which are intended to produce milk for human consumption, within
2 months of expected parturition.
5.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.